Retapamulin 1% Ointment and Clobetasol Propionate 0.05% Foam is More Efficacious than Vehicle Ointment and Clobetasol 0.05% Propionate Foam in the Treatment of Hand/Foot Dermatitis: A Single Center, Randomized, Double-blind Study

Madelaine Haddican, Rita V Linkner, Giselle Singer, Shelbi C Jim, Matthew Gagliotti, Gary Goldenberg, Madelaine Haddican, Rita V Linkner, Giselle Singer, Shelbi C Jim, Matthew Gagliotti, Gary Goldenberg

Abstract

Background: Staphylococcus aureus has been implicated in the pathogenesis of adult hand/foot dermatitis.

Objective: The authors hypothesized that retapamulin 1% ointment and clobetasol propionate 0.05% foam would decrease disease severity in subjects with hand/foot dermatitis and provide a higher clearance of Staphylococcus aureus colonization, when compared to vehicle (placebo) ointment and clobetasol propionate 0.05% foam.

Methods: Adult subjects with moderate to very severe hand/foot dermatitis had twice-daily topical application of clobetasol propionate 0.05% foam to hands/feet for 14 days and were randomized to apply either retapamulin 1% ointment or vehicle ointment twice daily to hands/feet and nares for five days.

Results: Seventy-three percent of subjects in the retapamulin/clobetasol group were clear/almost clear at Day 15 compared to 47 percent of subjects in the vehicle/clobetasol group (p-value of 0.04). The percentage of subjects who had both negative skin and nares cultures and were clear/almost clear was also statistically significant in favor of the retapamulin/clobetasol group at Day 15 (p-value of 0.05).

Limitations: Sample size, study population.

Conclusion: At Day 15, retapamulin 1% ointment with clobetasol propionate 0.05% foam was more efficacious than vehicle ointment and clobetasol propionate 0.05% foam for disease improvement and Staphylococcus aureus clearance in adult subjects with hand/foot dermatitis.

Figures

Figure 1
Figure 1
Study composition
Figure 2A
Figure 2A
Subject 1 (hand eczema) in the retapamulin/clobetasol treatment group
Figure 2B
Figure 2B
Subject 2 (foot eczema) in the retapamulin/clobetasol treatment group

Source: PubMed

3
Abonner